

# Maria Chiara Buscarinu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4712379/publications.pdf>

Version: 2024-02-01

67  
papers

2,145  
citations

304368

22  
h-index

253896

43  
g-index

70  
all docs

70  
docs citations

70  
times ranked

3544  
citing authors

#	ARTICLE	IF	CITATIONS
1	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 780-789.	2.8	370
2	Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. <i>Nature Immunology</i> , 2015, 16, 1174-1184.	7.0	296
3	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. <i>EBioMedicine</i> , 2021, 72, 103581.	2.7	184
4	Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS. <i>Neurology</i> , 2014, 82, 41-48.	1.5	128
5	Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 442-446.	1.4	107
6	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	1.7	86
7	A Candidate-Interactome Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63300.	1.1	66
8	Interferon- $\beta$ therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis. <i>Immunology and Cell Biology</i> , 2016, 94, 886-894.	1.0	61
9	Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis. <i>Neurotherapeutics</i> , 2018, 15, 68-74.	2.1	55
10	Epstein-Barr virus genetic variants are associated with multiple sclerosis. <i>Neurology</i> , 2015, 84, 1362-1368.	1.5	44
11	Twin studies in multiple sclerosis: A meta-estimation of heritability and environmentality. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1404-1413.	1.4	43
12	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , 2018, 265, 2851-2860.	1.8	43
13	The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology. <i>Frontiers in Immunology</i> , 2019, 10, 1916.	2.2	39
14	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1034-1040.	1.4	37
15	CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes. <i>Immunology Letters</i> , 2014, 158, 134-142.	1.1	36
16	Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. <i>CNS Drugs</i> , 2018, 32, 963-970.	2.7	35
17	Fingolimod vs dimethyl fumarate in multiple sclerosis. <i>Neurology</i> , 2018, 91, e153-e161.	1.5	35
18	Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?. <i>Frontiers in Immunology</i> , 2021, 12, 755333.	2.2	33

#	ARTICLE	IF	CITATIONS
19	A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials. <i>Scientific Reports</i> , 2017, 7, 45780.	1.6	31
20	Geographic Population Structure in Epstein-Barr Virus Revealed by Comparative Genomics. <i>Genome Biology and Evolution</i> , 2016, 8, 3284-3291.	1.1	29
21	IFN- $\gamma$ and multiple sclerosis: From etiology to therapy and back. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 221-228.	3.2	28
22	A multicentre observational analysis of Persistence to Treatment in the new multiple sclerosis era: the RESPECT study. <i>Journal of Neurology</i> , 2018, 265, 1174-1183.	1.8	23
23	Thymosin- $\alpha$ 1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 127-139.	1.4	23
24	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. <i>Frontiers in Neurology</i> , 2019, 10, 916.	1.1	21
25	Late-Onset MS: Disease Course and Safety-Efficacy of DMTs. <i>Frontiers in Neurology</i> , 2022, 13, 829331.	1.1	19
26	Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. <i>Journal of Neurology</i> , 2021, 268, 2922-2932.	1.8	18
27	Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 2238-2245.	1.8	15
28	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101461.	0.9	14
29	MAIT Cells and Microbiota in Multiple Sclerosis and Other Autoimmune Diseases. <i>Microorganisms</i> , 2021, 9, 1132.	1.6	14
30	Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1939-1947.	1.4	13
31	A cell type-specific transcriptomic approach to map B cell and monocyte type I interferon-linked pathogenic signatures in Multiple Sclerosis. <i>Journal of Autoimmunity</i> , 2019, 101, 1-16.	3.0	12
32	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021, 28, 1299-1307.	1.7	12
33	A Case of Double Standard: Sex Differences in Multiple Sclerosis Risk Factors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3696.	1.8	12
34	Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study. <i>Frontiers in Neurology</i> , 2021, 12, 657973.	1.1	11
35	IFN- $\gamma$ Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 668-681.	0.5	10
36	Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2018, 324, 165-171.	1.1	10

#	ARTICLE	IF	CITATIONS
37	Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1272-1278.	0.9	10
38	SARS-CoV-2 meta-interactome suggests disease-specific, autoimmune pathophysiologies and therapeutic targets. <i>F1000Research</i> , 2020, 9, 992.	0.8	10
39	Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. <i>Journal of Neurology</i> , 2022, 269, 3301-3307.	1.8	9
40	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 535-542.	1.7	8
41	Evidence for Detrimental Cross Interactions between Reactive Oxygen and Nitrogen Species in Leber's Hereditary Optic Neuropathy Cells. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-9.	1.9	7
42	Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate. <i>Neurology</i> , 2016, 87, 952-953.	1.5	7
43	Autoimmune Encephalitis and CSF Anti-GluR3 Antibodies in an MS Patient after Alemtuzumab Treatment. <i>Brain Sciences</i> , 2019, 9, 299.	1.1	7
44	Genome-Wide Multiple Sclerosis Association Data and Coagulation. <i>Frontiers in Neurology</i> , 2019, 10, 95.	1.1	7
45	Disentangling the molecular mechanisms of multiple sclerosis: The contribution of twin studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 111, 194-198.	2.9	7
46	Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study. <i>Journal of Neurology</i> , 2022, 269, 1610-1617.	1.8	7
47	Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study. <i>Journal of Neurology</i> , 2020, 267, 694-702.	1.8	6
48	EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, e876.	3.1	6
49	Viruses and neuroinflammation in multiple sclerosis. , 0, , .		6
50	Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1937-1943.	1.4	6
51	Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority. <i>Frontiers in Neurology</i> , 2019, 10, 695.	1.1	5
52	Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Dimethylfumarate. <i>Frontiers in Neurology</i> , 2021, 12, 683398.	1.1	5
53	Reworking GWAS Data to Understand the Role of Nongenetic Factors in MS Etiopathogenesis. <i>Genes</i> , 2020, 11, 97.	1.0	4
54	Multiple sclerosis genetic and non-genetic factors interact through the transient transcriptome. <i>Scientific Reports</i> , 2022, 12, 7536.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Shared environmental effects on multiple sclerosis susceptibility: conflicting evidence from twin studies. <i>Brain</i> , 2014, 137, e287-e287.	3.7	3
56	Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS. <i>Neurology</i> , 2014, 83, 380-381.	1.5	2
57	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the irems group. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102394.	0.9	2
58	Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS. <i>Neurology</i> , 2014, 83, 293-293.	1.5	1
59	B cell IRF1 pathway is dysregulated in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 275, 1.	1.1	1
60	Intestinal permeability in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 275, 54.	1.1	1
61	A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117430.	0.3	1
62	Characterization of Epstein-Barr virus genotypes in multiple sclerosis through next generation sequencing approaches. <i>Journal of Neuroimmunology</i> , 2014, 275, 79.	1.1	0
63	Chemical Elements and Oxidative Status in Neuroinflammation. , 2017, , 67-81.		0
64	Bacille Calmette-Guérin (BCG) Vaccine in Neuroinflammation. , 2018, , 25-38.		0
65	Informing MS patients on treatment options: a consensus on the process of consent taking. <i>Neurological Sciences</i> , 2020, 41, 2249-2253.	0.9	0
66	GWAS-associated variants, non-genetic factors, and transient transcriptome in multiple sclerosis etiopathogenesis: A colocalization analysis. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118157.	0.3	0
67	Leptomeningitis in a Person with Radiologically Isolated Syndrome and Latent Tuberculosis: A Case Report with Implications for Clinical Research. <i>Journal of Medical Imaging and Case Reports</i> , 2018, 02, .	0.1	0